$0.01
(Market cap
$4 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2 %
-
ROCE
-- %
-
Industry P/E
27.09
-
EV/EBITDA
-0.9
-
Debt to Equity
1.8
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
118,109,000
8 Years Aggregate
CFO
$-550.81 Mln
EBITDA
$-646.50 Mln
Net Profit
$-647.01 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gritstone Oncology Inc (GRTS)
| -98.4 | 54.1 | -93.5 | -97.6 | -85.7 | -67.2 | -- |
|
BSE Sensex*
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
Gritstone Oncology Inc (GRTS)
| -40.9 | -73.2 | 226.4 | -56.1 | -41.9 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Gritstone Oncology Inc (GRTS)
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate,... which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California. On October 10, 2024, Gritstone bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
Co-Founder, President, CEO & Director
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
-
Co-Founder, President, CEO & Director
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
-
Headquarters
EmeryVille, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Gritstone Oncology Inc (GRTS)
What is the current share price of Gritstone Oncology Inc (GRTS) Today?
The share price of Gritstone Oncology Inc (GRTS) is $0.03 (NASDAQ) as of 27-Nov-2024 09:30 EDT. Gritstone Oncology Inc (GRTS) has given a return of -85.75% in the last 3 years.
What is the current PB & PE ratio of Gritstone Oncology Inc (GRTS)?
Since, TTM earnings of Gritstone Oncology Inc (GRTS) is negative, P/E ratio is not available.
The P/B ratio of Gritstone Oncology Inc (GRTS) is 0.21 times as on 27-Nov-2024, a 97 discount to its peers’ median range of 6.06 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
What is the 52 Week High and Low of Gritstone Oncology Inc (GRTS)?
The 52-week high and low of Gritstone Oncology Inc (GRTS) are Rs -- and Rs -- as of 24-May-2026.
What is the market cap of Gritstone Oncology Inc (GRTS)?
Gritstone Oncology Inc (GRTS) has a market capitalisation of $ 4 Mln as on 27-Nov-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Gritstone Oncology Inc (GRTS)?
Before investing in Gritstone Oncology Inc (GRTS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.